News J&J bids to extend prostate cancer uses for Akeega J&J is hoping the AMPLITUDE study results will make Akeega the first drug in the PARP inhibitor class for castration-sensitive prostate cancer.
News BMS' radiopharma unit builds with $1.35bn Philochem deal Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.
News ASCO 25: J&J combo pill may see wider use in prostate cancer AMPLITUDE study of J&J's Akeega could extend the use of PARP inhibitors to hormone-responsive prostate cancer.
Oncology Prostate cancer: HCPs discuss emerging treatments, artificia... In March, the UK marked Prostate Cancer Awareness Month - a period dedicated to boosting recognition and tackling stigma of a cancer that affects approximately one in eight men nationwide.<
News UK first to approve Rotop's prostate cancer imaging agent The UK has given a world-first approval to Rotop's RoTecPSMA, a new imaging agent for detecting lesions in men with prostate cancer.
News Rishi Sunak becomes prostate cancer ambassador Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador for its campaign for a national screening programme.
News Third death reported with a Sarepta gene therapy A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face